Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays by de Jager, Wilco et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Immunology
Open Access Research article
Prerequisites for cytokine measurements in clinical trials with 
multiplex immunoassays
Wilco de Jager*1,2,3, Katarzyna Bourcier4, Ger T Rijkers3,5, 
Berent J Prakken†1,2,3 and Vicki Seyfert-Margolis†4
Address: 1Department of Pediatric Immunology, Centre for Molecular and Cellular Intervention (CMCI), University Medical Centre Utrecht, 
Utrecht, The Netherlands, 2EUREKA Institute of Translational Medicine, Siracusa, Italy, 3Immune Tolerance Network, Luminex Core Facility, 
Utrecht, the Netherlands, 4Immune Tolerance Network, University of California, San Francisco, CA, Bethesda, MD, USA and 5Laboratory of 
Medical Microbiology and Immunology, Sint Antonius Hospital, Nieuwegein, the Netherlands
Email: Wilco de Jager* - wjager@umcutrecht.nl; Katarzyna Bourcier - kbourcier@immunetolerance.org; Ger T Rijkers - ger@rijkers.nl; 
Berent J Prakken - b.prakken@umcutrecht.nl; Vicki Seyfert-Margolis - vseyfert@immunetolerance.org
* Corresponding author    †Equal contributors
Abstract
Background: Growing knowledge about cellular interactions in the immune system, including the
central role of cytokine networks, has lead to new treatments using monoclonal antibodies that
block specific components of the immune system. Systemic cytokine concentrations can serve as
surrogate outcome parameters of these interventions to study inflammatory pathways operative
in patients in vivo. This is now possible due to novel technologies such as multiplex immunoassays
(MIA) that allows detection of multiple cytokines in a single sample. However, apparently trivial
underappreciated processes, (sample handling and storage, interference of endogenous plasma
proteins) can greatly impact the reliability and reproducibility of cytokine detection.
Therefore we set out to investigate several processes that might impact cytokine profiles such as
blood collecting tubes, duration of storage, and number of freeze thawing cycles.
Results:  Since under physiological conditions cytokine concentrations normally are low or
undetectable we spiked cytokines in the various plasma and serum samples. Overall recoveries
ranged between 80-120%. Long time storage showed cytokines are stable for a period up to 2 years
of storage at -80°C. After 4 years several cytokines (IL-1α, IL-1β, IL-10, IL-15 and CXCL8)
degraded up to 75% or less of baseline values. Furthermore we show that only 2 out of 15 cytokines
remained stable after several freeze-thawing cycles. We also demonstrate implementation of an
internal control for multiplex cytokine immunoassays.
Conclusion: All together we show parameters which are essential for measurement of cytokines
in the context of clinical trials.
Background
Better characterization of cellular processes and cytokine
pathways in a variety of diseases ranging from allergy and
autoimmunity to cancer has lead to new treatments that
use monoclonal antibodies which specifically block com-
ponents of the human immune system including cytokine
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pathways [1-6]. These new therapeutic strategies, which
modulate inflammatory processes of the immune system,
can induce major changes in the downstream cytokine
milieu. Indeed, the aftermath of the TGN1412 phase I
clinical trial in March 2006 revealed that the life threaten-
ing adverse events were the consequence of a rapid onset
severe cytokine storm [7,8]. This example underscores the
importance of monitoring cytokines during experimental
therapies which are based on or could influence cytokine
pathways or cytokine producing cells.
Cytokines are small secreted extra-cellular signaling
(glyco-) proteins which regulate cell-mediated immune
responses. They are effector molecules that can instantly
alter the quality of the immune response. The effect of a
particular cytokine on a given cell depends on the
cytokine, its extra cellular abundance, the presence (or
absence) of the complementary receptor on the cell sur-
face, and downstream signals activated by receptor bind-
ing [9]. As cytokines reflect the local or systemic
inflammatory milieu, they could serve as biomarkers for
potential clinical effect of the therapeutic interventions.
As cytokines act in networks, measurements of single
cytokines is of limited value, emphasizing the need for
simple, reliable, cost effective, and reproducible technol-
ogy for the measurement of multiple cytokines. Several
methodologies have been developed and employed for
quantification of secreted cytokines. Immunoassays such
as ELISA are currently the most commonly used tech-
niques to quantify cytokines due to the high specificity
and sensitivity [10]. Built on the same principle, more
rapid, automated, and high throughput methods have
been developed [11]. More recently a bead-based multi-
plex immunoassays (MIA) with the FlowMetrix (currently
know as xMAPtm technology, Luminex, Austin TX USA)
has been increasingly used for detection of multiple
cytokines in a single sample [12].
A number of parameters can affect adequate and reliable
measurements of cytokine levels in biological specimens
collected in a (multicenter) clinical trial including the tim-
ing of sampling, sample handling and storage, and even
the choice of plasma or serum (various blood collection
tubes). In some cases, such as inflammatory diseases,
numerous endogenous plasma proteins such as heter-
ophilic antibodies, soluble receptors, complement,
immune complexes, lysosyme, collectins (lectins) and
some acute phase proteins can also interfere with immu-
noassays such as MIA and ELISA [13].
We and others have previously shown that technical pre-
requisites for an "in-house" multiplex immunoassay have
done comparison studies with ELISA's. In this study we set
out to describe parameters which are critical for obtaining
accurate cytokine measures from clinical samples, when
using a multiplex cytokine detection platform, such as
Luminex.
Methods
Serum and Plasma collection
Blood samples were collected from 4 healthy volunteers
using the following blood collection tubes; normal clot-
ting tube (SST II Advance, BD Biosciences) for serum and
sodium heparin (NH), EDTA, or sodium citrate (NC)
tubes for collecting plasma (all BD Biosciences) in the
morning on 2 following days. All samples were kept on
room temperature and were spun within 1 hour at 700 ×
g at room temperature. Cell free plasma or serum was aliq-
uoted and stored at -80°C until analysis. Before analysis
all thawed samples were centrifuged through a polypro-
pylene centrifuge tube containing a 0.22 μm nylon mem-
brane (Spin-X column; Corning, Corning, NY, USA) to
remove debris. Non-specific heterophilic antibodies, such
as natural polyspecfic antibodies, idiotypic antibodies
and natural rheumatoid factors, were pre-absorbed, with-
out loss of cytokine concentration, from all samples with
protein-L pre coated ELISA plates (Pierce, Rockford, IL,
USA) as described previously [14]. 100 μl of sample well
was incubated for 1 hour at room temperature under con-
tinuous shaking. As this incubation step removes 60-80%
of the total immunoglobulin fraction without depleting
natural occurring cytokines [14]samples were then
diluted with 10% v/v normal rat and mouse serum (1:1
ratio; Rockland, Gilbertsville PA, USA) and incubated for
10 additional minutes at room temperature to block any
residual interfering proteins which are able to bind (a)
specifically to rat or mouse immunoglobulins. Animal
serum batches were tested upfront, and only used when
they did not show any cross-reactivity within the assay.
All samples obtained were approved for collection by the
medical ethical committee of the UMC Utrecht. Informed
consent was obtained from each individual who donated
samples.
Cytokine induction in whole blood cultures
Cytokine production was induced using sodium heparin
whole blood samples that were stimulated with a combi-
nation of 100 ng/ml lippopolysaccharide (LPS, Sigma
Sigma-Aldrich, Zwijndrecht, the Netherlands) and 7 μg of
phytohemagglutinin (PHA; Murex Biotech, Dartford,
United Kingdom) per ml. Ten μl of the LPS/PHA cocktail
was added to 1 ml whole blood and cultured for 6, 24 and
48 h at 37°C in 5% CO2. After culture the samples were
centrifuged, and supernatants of all 3 time points were
pooled and frozen at -80°C until further analyses by MIABMC Immunology 2009, 10:52 http://www.biomedcentral.com/1471-2172/10/52
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Internal control sample
Sodium heparin blood samples were collected from 4
healthy volunteers and peripheral blood mononuclear
cells (PBMC) were isolated by Ficoll Isopaque density gra-
dient centrifugation (1.077 g/cm3; Amersham Pharmacia
Biotech AB, Uppsala, Sweden). Cultures were performed
in RPMI 1640 tissue culture medium supplemented with
100 U/ml penicillin-streptomycin, 2 mM L-glutamine and
10% heat inactivated fetal bovine serum (all Invitrogen,
Gaithersburg, MD USA). We have shown previous that
protein resources could interfere with cytokine assays
[15]. FBS was tested upfront to show it did not induce cell
activation/proliferation or cross reaction with human
cytokines. Our batch of FBS was used for culturing
PBMC's at different concentrations (5, 10 and 40%, dur-
ing 96 hrs) and did not show any activation, measured by
3 H incorporation [16] or induction of cytokines by
human PBMC measured by MIA (data available upon
request). Cells were cultured in round bottom microtiter
plates (Greiner, Alphen aan de Rijn, The Netherlands) at
2 × 105 cells per well and incubated for 24 to 48 hours at
37°C. A combination of 100 ng/ml LPS (Sigma-Aldrich)
and 7 μg of PHA (Murex Biotech) per ml, was added to
each well, after culture cell free supernatants were col-
lected, pooled and frozen in 200 μl aliquots at -80°C. This
sample was included in every MIA as an internal control
(see below).
Multiplex Immunoassay
The antibody pairs and recombinant proteins used were
purchased from commercial sources as described previ-
ously [14]. Carboxylated polysterene microspheres were
purchased from Bio-Rad Laboratories (Hercules CA,
USA). Covalent coupling of the capture antibodies to the
microspheres was performed as previously described
[14,15]. Calibration curves from recombinant protein
standards were prepared using two-fold dilution steps in
serum diluent (R&D Systems, Abingdon, United King-
dom) as previously described [14]. Samples were meas-
ured and blank values were subtracted from all readings.
All assays were carried out directly in a 96 well 1.2 μm fil-
ter plate (Millipore, Billerica, MA, USA) at room tempera-
ture and protected from light. A mixture containing 1000
microspheres per mediator (total volume 10 μl/well) was
incubated together with a standard, sample or blank for 1
hour at room temperature. Next, 10 μl of a cocktail of
biotinylated antibodies (16.5 μg/ml each) was added to
each well and incubated for an additional 60 minutes.
Beads were then washed with phosphate buffered saline
(PBS) supplemented with 1% bovine serum albumin
(BSA) and 0.5%-Tween 20 at pH of 7.4. After incubation
for 10 minutes with 50 ng/well streptavidin R-phyco-
erythrin (BD Biosciences, San Diego CA, USA) and wash-
ing twice with PBS-1% BSA- 0.5%-Tween 20 pH 7.4
fluorescence intensity of the beads was measured in a final
volume of 100 μl HPE-buffer (Sanquin Reagents, Amster-
dam, the Netherlands). Measurements and data analysis
of all assays were performed using the Bio-Plex system in
combination with the Bio-Plex Manager software version
4.1 using five parametric curve fitting (Bio-Rad Laborato-
ries). Performance characteristics of the multiple immu-
noassay, and biological variation in plasma samples of
healthy controls are described elsewhere [14,15,17,18].
Statistical analysis
All results are expressed as mean ± standard deviation
(SD). A probability (p) less then 0.05 was considered sig-
nificant different. For the calculation of the prolonged
storage and stability of cytokines during freeze -thawing
cycles, baseline values were set at 100% and follow-up
points were related to this base value. All statistical analy-
ses were performed using the statistical package for the
social sciences (SPSS) software version 12.0.1 (SPSS, Chi-
cago, IL, USA).
Results
Effect of anticoagulant on cytokine measurements
To investigate potential effects of different blood antico-
agulants on cytokine measurements by MIA, blood of 4
healthy volunteers was drawn in various tubes for serum,
sodium heparin plasma, EDTA plasma and citrate plasma
and cytokine profiles were measured. Obviously data
analysis becomes complex when a large number of pro-
teins are measured using a multiplex assay. Therefore we
digitized our data creating color profiles of the protein
spectrum as previously described[15]. Using this kind of
representation protein fingerprints can be plotted as com-
parative data between different conditions or as quantita-
tive data for an individual subject. As an example showing
integral cytokine profiles the various blood drawing
tubes. As expected, most cytokines were present in low or
undetectable levels (figure 1). Only IL-18 was detectable
and did not vary between the different sample collection
tubes. In contrast IL-6 levels measured higher in citrate
plasma whereas for CXCL8 highest concentrations were
obtained from serum (figure 1).
As most cytokines are not expressed, individual person to
person variation could only be calculated using IL-18 con-
centrations. Therefore blood samples were collected of the
same individuals on 2 following days to study the varia-
tion between individuals using all various blood collect-
ing tubes. Variations in IL-18 levels were similar for all
different blood collection tubes and ranged between 6.1-
9.8% depending on each individual.
Many studies have shown that various diseases have
increased levels of cytokines in plasma or serum. As our
healthy controls show no or low concentrations of
cytokines we spiked the various plasma and serum sam-BMC Immunology 2009, 10:52 http://www.biomedcentral.com/1471-2172/10/52
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ples of all donors with 1000 pg/ml of each cytokine to
mimic increased concentrations of cytokines as shown in
different diseases. This was done as we are in a pediatric
setting and could not recruit any diseased individuals to
test different blood tubes due to ethical restriction.
Recovery was measured in 2 assays on 2 consecutive days
using a spiked sample, and a non-spiked sample as back-
ground. Overall recoveries of the spiked cytokines in the
various serum and plasma samples ranged between 80 -
120% (figure 2). However, there were some marked
inconstancies in recovery. In serum a significantly higher
recovery for CXCL8 was found (113%, p < 0.05) whereas
IL-6 levels were slightly lower in serum as compared to
plasma samples. Sodium heparin and EDTA plasma
showed a stable recovery off all cytokines, with the excep-
tion of IL-15 and IL-18 which was decreased in EDTA
plasma (85% for IL-6, 87% for IL-18). The recovery of
these two cytokines was significantly lower compared to
the other samples (p < 0.05 in both cases). In citrate
plasma lower recoveries were found for IL-1β, IL-2 and IL-
6 (figure 2). Sodium heparin plasma showed the most
constant recovery of all cytokines tested and therefore is
the preferred anticoagulant.
Stability of cytokines during long time storage
In most clinical trials the inclusion period, intervention
and follow-up periods run over a periods spanning several
years. When the measurements are not performed
directly, but at the end of the study, stability of cytokines
has to be guaranteed during prolonged storage. As shown
above, plasma from healthy individuals contains only low
levels of most cytokines, sodium heparin whole blood
from 4 individuals was stimulated with a combination of
LPS and PHA which result in production of a wide array
of cytokines. Cells were removed by centrifugation and
samples were stored at -80°C. To determine cytokine deg-
radation during long time storage, samples were meas-
ured directly (baseline) and at various time points
afterwards (up to 4 years). As shown in figure 3 most
cytokines are stable for up to two years. Degradation of
cytokines is observed for IL-13, IL-15, IL-17 and CXCL8
already within one year of storage, whereas IL-2, IL-4, IL-
12 and IL-18 are stable for up to 3 years. Other cytokines,
such as IL-1α, IL-1β, IL-5, IL-6, and IL-10 degraded up to
50% or less of baseline values within 2-3 years of storage
(figure 3).
Cytokine stability upon freeze - thawing
Next we questioned how stability of cytokines is influ-
enced by freeze thawing cycles. Therefore a cytokine pro-
file was induced by stimulation of sodium heparin whole
blood as described above. From the same samples, aliq-
uots were subjected to multiple freeze - thawing cycles and
cytokines were measured. IL-6, and IL-10 are stable
throughout multiple freeze thawing cycles, whereas IL-4,
IL-13, IL-15, IL-17, TNFα, IFNγ and CXCL8 levels either
rise (IL-4 and TNFα) or drop (IL-13, IL-15, IL-17, IFNγ
and CXCL8) after one or more freeze - thawing cycles (fig-
ure 4). These data indicate that samples for cytokine meas-
urements should not have been subjected to repeated
freeze-thaw cycles.
Quality control for multiplex immunoassay
As shown above, cytokines degrade at -80°C during long
time storage, such that samples should be measured with
a timely interval using a robust, reliable, and consistent
assay. Therefore it is essential to implement a QC system
for multiplex immunoassays. When an in-house assay is
developed for a bead based MIA, all the different steps of
the assay must be monitored for the use with samples
from clinical trials. Coupling of primary antibodies to the
microspheres is rather straightforward and QC assessment
of this procedure is previously described[15]. However, an
internal control sample is needed to monitor several other
parameters of the assay. We measured our internal control
sample undiluted and diluted 1:100 with HPE buffer over
a time period of 1 year to test for consistency. Intra-assay
variation was <7% and inter-assay variation ranged
between 5 and 20% (data not shown). We set our cut off
value on the 2-SD range of the mean measurement of this
sample run repeatedly over 20 different days. The range
was chosen since cytokine concentrations of biological
control samples will be either at the lower or upper end of
the standard curve. However, due to this approach, the
intra-assay CV of a low expressed cytokine will therefore
more frequently fall outside the 2-SD boundaries then a
Cytokine profiles in different blood collection tubes Figure 1
Cytokine profiles in different blood collection tubes. 
Blood samples were obtained from 4 healthy volunteers 
using various blood collection tubes after centrifugation cell 
free plasma (sodium heparin plasma, EDTA plasma and 
sodium citrate plasma) and serum cytokine levels were meas-
ured using a multiplex assay. Color profiles were generated 
using geometric mean values and plotted using a semi log 
scale as previously described [14].
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high expressed cytokine. Intra-assay variation is higher for
cytokines present in relative low concentrations as com-
pared with a cytokine which is abundantly expressed an
internal control sample (figure 5A/B).
Inter-assay variation will also be high in case of poor anti-
body performance. This phenomenon can be easily
detected by comparison of the relevant standard curves.
Normally, inter-assay comparison of standard curves will
show overlapping or parallel curves (figure 5A and 5B)
but when the detection and/or matching catching anti-
bodies perform poorly this will result in dispersed graph
pattern with variable slopes (figure 5C).
Finally, when it is acknowledged that cytokines in plasma
samples can deteriorate over time, even when stored at -
80°C, the same hold true for the recombinant proteins
used for generating standard curves. When such degrada-
tion occurs, the standard curves will shift to lower fluores-
cence intensity. This will result in apparent higher values
of the internal control samples as wells as higher
cytokines concentrations of clinical samples when similar
concentrations recombinant proteins are used for generat-
ing standard curves (figure 5D).
Discussion
Cytokines are involved in the effector phase of all inflam-
matory diseases, and thus, could serve both as biomarkers
for disease severity and as targets for therapy. Anti
cytokine therapy was first introduced in the early eighties
of the last century, with the first successful application of
an anti cytokine therapy trial involving anti-IFN-alpha
Recovery of spiked cytokines in various types of plasma and serum Figure 2
Recovery of spiked cytokines in various types of plasma and serum. Cytokines (1000 pg/ml) were spiked in various 
types of plasma and serum. Recoveries were measured using a multiplex immunoassay. Se serum, NH sodium heparin plasma, 
E EDTA plasma, CP sodium citrate plasma. Shown are means ± SD.
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antibodies in patients with Rheumatoid Arthritis [19].
Since then, several monoclonal antibodies against
cytokines or cytokine receptors as well as other immune
modulating drugs are used for a variety of diseases [1-6].
Because of the interconnectivity of immunoregulatory cir-
cuits, blocking or activation of specific components of the
immune system can result in major changes in the
cytokine milieu, which may lead to unexpected side
effects. As an example, the development of systemic lupus
erythematosus-like symptoms during anti TNFα therapy
in Rheumatoid Arthritis patients is due to accumulation
of another cytokine, IFN-α, a direct consequence of the
TNFα blockade [20,21]. Careful monitoring of cytokines
is necessary to assess the impact of drugs that influence
the immune response, particularly during early phase
clinical trials. As multiple cytokines may be effected, tech-
niques for measuring panels of cytokines are of most
value.
The microsphere-based multiplex immunoassay measure-
ment allows the simultaneous analysis of multiple
secreted cytokines in a variety of bodily fluids [12]. This
technology can detect up to 100 different mediators using
as little as a 50 μl sample volume [11,22,23], making this
technology very useful in clinical trials, especially when
volumes are limited.
For a multiplex assay to perform adequately the condi-
tions should be optimal for every individual component.
Long time stability of induced cytokine profiles Figure 3
Long time stability of induced cytokine profiles. Sodium heparin whole blood from 3 individuals was stimulated with a 
combination of LPS and PHA to induce cytokine profiles. Samples were measured at baseline (BL) and at various time points. 
Baseline value was set at 100%. Shown are means ± SD.
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However, many clinical trial designs underestimate the
impact of parameters which can impact reliable cytokine
measurements such as sample handling and storage, and
quality control of the platform used for cytokine detec-
tion.
First, timing of sampling is important. Cytokines are
under neuroendocrine control and thus have a diurnal
rhythm [24,25]. Many pro-inflammatory cytokines, such
as IL-1, IL-6, TNFα and IFNγ are linked to melatonin and
peak early in the morning [26]. Rheumatoid arthritis
patients have increased IL-6 levels in the morning which
correlate with clinical symptoms [27,28]. Besides diurnal
rhythms, exercise also impacts cytokine levels in blood, as
after exercise, among others, muscle cells release IL-6 and
which will result in temporarily elevated cytokine levels
[29,30].
Secondly, proper sample handling and storage is critical
for reliable measurement of circulating cytokines. When
sampling takes place plasma and serum should be sepa-
rated as soon as possible. In this study we kept our sam-
ples at room temperature and froze plasma and serum
sample at -80°C within 1 hour after blood draw. A delay
of sample processing containing cellular components will
lead to different cytokine expression profiles by either
degradation, absorption, or cellular production of
cytokines [31]. Furthermore, a careful consideration
should be made for the use of blood collection tubes dur-
ing trial design. During clotting or by centrifugation,
Recovery of cytokines after multiple freeze - thawing cycle Figure 4
Recovery of cytokines after multiple freeze - thawing cycle. Aliquots of the same LPS/PHA stimulated samples were 
freshly thawed or underwent multiple freeze - thawing cycles and cytokines were measured simultaneously. Shown are means 
± SD.
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Longitudinal assay performance using an internal control sample Figure 5
Longitudinal assay performance using an internal control sample. Left panel shows variability in time of observed 
cytokine values of the internal control sample for IL-1β (A), IL-4 (B), I-L6 (C) and TNFα (D) in 50 consecutive runs covering a 
period of 12 months. Right-hand panel shows overlays of 4 separate standard curves of the corresponding cytokines.
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platelets can release various cytokines such as IL-6 and
CXCL8 [32]. Furthermore cytokine binding to, or release
from their soluble receptors can result in an under- or
overestimation during spiking assays. For instances spe-
cific binding and release of IL-1, IL-6, and IL-18 towards
their soluble receptor is well documented [33,34]. This
phenomenon can at least partly account for the large var-
iation found in our spiking assays (figure 2). We show
here that the use of various blood collection tubes signifi-
cantly affects cytokine measurement, with sodium
heparin tubes showing most consistent cytokine recovery.
Cytokines should be stored below -80°C for longer time.
Although degradation will occur also at this temperature
after longer periods of storage (figure 3), sample storage at
temperatures of -20°C degradation occurs at faster pace
[35]. Furthermore multiple freeze - thawing cycles also
affect cytokine recovery in clinical samples. Although
most cytokines are stable in a high protein matrix such as
plasma, during the first freeze - thawing cycle an addi-
tional freeze - thawing cycle should be avoided at any time
(figure 4).
The third critical factor is the quality control of the plat-
form used. Obviously, assay performance is strongly
dependent on the quantity of antibodies used as well
matrix effects. We and others showed that quality control
of different components (e.g. recombinant proteins, sam-
ple diluents, microsphere coupling etc.) of the multiplex
immunoassay can be performed and implemented easily
in a in-house assay [15,22,36]. In commercially available
kits internal QC samples are mostly lacking. However
some commercial kits suggest to use several dilutions of
the recombinant standard curves as an spiked in QC sam-
ple [37]. Though, the amount of recombinant standards
and diluents for construction of calibration curves are suf-
ficient for a single kit and can not be used for long-term
monitoring of performance [38]. With the use of an in-
house assay, standard curves can either be constructed
with or calibrated on NIBSC/WHO standards. However,
when comparing different commercial assays using these
NIBSC/WHO standards, large differences in observed
cytokine concentrations are found [39,40]. Use of differ-
ent antibodies (clones) is only part of the explanation for
this phenomenon. Other, more likely culprits are matrix
effects, e.g. because of heterophilic antibodies that are
often present in human inflammatory diseases [41]. We
have shown previously that removing antibodies with
protein-L followed by blocking with 10% rat/mouse
serum is sufficient to reduce such matrix effects [14] where
others demonstrated that blocking with fetal bovine
serum (FBS), was effective in only a minority of the sam-
ples [42]. Since FBS does not contain immunoglobulins,
this underscores the possibility that proteins, other than
antibodies, can interfere with the assay. Other matrix
effects, such as protein content and pH can also influence
the assay performances and should be standardized when
using this assay for clinical trial design [11,43]. For sam-
ples with high protein content such as plasma or serum
most commercial assays require dilutions for ideal assay
performance, while an in-house assay condition can be set
in such a way that samples do not have to be diluted.
The necessity of sample dilution is a major drawback,
since it proportionally reduces assay sensitivity. This has
major impactions for detection of cytokines such as IL-4,
which is already biological active in the lower pg/ml
range. Another disadvantage for dilution is that cytokines
can be bound to their soluble receptors or binding pro-
teins, resulting in biological non-active cytokines. This
binding can, at least partly, be reversed when dilutions are
applied, thus resulting in over estimation of the true
cytokine concentration [34,44].
However, previous studies have shown that without
addressing matrix effects in undiluted samples false posi-
tive findings are found in up to 90% of healthy individu-
als which could be reversed by incubating with rodent
serum [22]. However blocking with rodent serum alone is
not sufficient to remove false positive values from patients
which are positive for auto antibodies such as rheumatoid
factor [11]. Therefore in this study, we applied a relative
small dilution (10 v/v %) with rodent serum after protein-
L incubation to avoid a-specific binding of matrix pro-
teins.
All points described concerning the biological properties
of cytokines, such as long time stability and freeze thaw
cycles are not only relevant multiplex immunoassays, but
also be applied to other technology used for cytokine
measurements in a clinical (trial) setting. Multiplex
immunoassays have many advantages for biomarker
development in clinical settings. It can measure multiple
mediators at once and has the flexibility to easily add any
new target protein to the assay. This study underlines that
multiplex immunoassays have many advantages for the
use in clinical trials, provided that a strict quality control
system is in place.
Conclusion
In this study we set out to investigate several processes that
might impact cytokine profiles such as blood collecting
tubes, duration of storage, and number of freeze thawing
cycles. Concluding from the data we present here in this
study we suggest to process clinical sample as soon as pos-
sible (within 1 hour), and store them at -80°C not longer
then 2 years for cytokine analysis without any freeze -
thawing cycle. Furthermore we recommend preparing an
internal control sample which is applicable for the sam-
ples of interest, which is kept under similar conditions asBMC Immunology 2009, 10:52 http://www.biomedcentral.com/1471-2172/10/52
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clinical sample (stored at -80°C, not longer then 2 years,
without freeze -thawing cycles). Single use aliquots of this
sample can be a freshly prepare as quality control sample
for each assay.
In the context of clinical trial design in which cytokine
measurements play a role, these apparently trivial under-
appreciated processes described here can greatly impact
the reliability and reproducibility cytokine measurements
and should be taken into account when designing future
clinical trials.
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